Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer’s continuum when only subtle changes in Aβ pathology are detected
Marc Suárez‐Calvet(Pasqual Maragall Foundation), Natàlia Vilor‐Tejedor(Radboud University Nijmegen), Annabella Beteta, Alba Cañas, José María Gónzalez‐de‐Echávarri(Pasqual Maragall Foundation), Albina Polo, Gonzalo Sánchez‐Benavides(Pasqual Maragall Foundation), Kaj Blennow(Sahlgrenska University Hospital), Juan Lantero‐Rodriguez(University of Gothenburg), Sherezade Fuentes, Irene Cumplido, Anna Soteras, Carles Falcón, Erik Stoops(ADx NeuroSciences), Sandra Pradas, José Luís Molinuevo(Pasqual Maragall Foundation), Eider M. Arenaza‐Urquijo(Pasqual Maragall Foundation), Paula Marne, Aleix Sala‐Vila(Instituto de Salud Carlos III), Raffaele Cacciaglia, Mahnaz Shekari(Universitat Pompeu Fabra), Thomas K. Karikari(University of Pittsburgh), Jordi Huguet, Gemma Salvadó(Lund University), Marc Vilanova(Pasqual Maragall Foundation), Laura L. Hernandez(University of Wisconsin–Madison), Juan Domingo Gispert(Lund University), Grégory Operto(Pasqual Maragall Foundation), Maria Emilio, Ruth Dominguez, Oriol Grau‐Rivera(Pasqual Maragall Foundation), Gwendlyn Kollmorgen(Roche Pharma AG (Germany)), Gema Huesa, Eugeen Vanmechelen(ADx NeuroSciences), Henrik Zetterberg(University of Wisconsin–Madison), Tania Menchón, Carolina Minguillón(Pasqual Maragall Foundation), Marta Milà‐Alomà(University of California, San Francisco), Carme Deulofeu, Karine Fauria(Pasqual Maragall Foundation)
Cited by 411
Related Papers
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
|Alzheimer s & Dementia|2018|10.4k
Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment
|Journal of Internal Medicine|2004|5k
A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease
|Alzheimer s & Dementia|2014|3.1k
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
|Alzheimer s & Dementia|2024|2.3k
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
|New England Journal of Medicine|2014|2k